TY  - JOUR
A1  - Lange, Christian
A1  - Jacobson, Ira M.
A1  - Rice, Charles M.
A1  - Zeuzem, Stefan
T1  - Emerging therapies for the treatment of hepatitis C
T2  - EMBO molecular medicine
N2  - Opportunities to treat infection with hepatitis C virus (HCV) are evolving rapidly. From the introduction of interferon-α monotherapy in 1992 to the approval of telaprevir- and boceprevir-based triple therapies with pegylated interferon-α and ribavirin in 2011, the chances of curing patients infected with HCV genotype 1 have improved from <10% to approximately 70%. Significant further improvements are on the horizon, which may well cure virtually all hepatitis C patients with an all-oral, interferon-free regimen in the very near future. These exciting developments are reviewed in the present article.
KW  - directly acting antiviral agents
KW  - hepatitis C virus
KW  - interferon-free
KW  - NS3-4A protease inhibitor
KW  - NS5B polymerase inhibitor
Y1  - 2013
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/34713
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-347134
SN  - 1715-4684
SN  - 1757-4676
N1  - © 2013 The Authors. This is an open access article under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/3.0/ , which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
VL  - 6
IS  - 1
SP  - 4
EP  - 15
PB  - Wiley-VCH
CY  - Weinheim
ER  -